Advertisement

Invasive Melanoma

  • David Panther
  • David G. Brodland
Chapter

Abstract

Melanoma remains one of few malignancies with increasing incidence. Surgical removal of invasive melanoma is the first and most important therapeutic intervention. Historically, margins of up to 5 cm have been recommended for a wide local excision (WLE). However, randomized controlled trials comparing margin width have significantly narrowed the size of an appropriate WLE to 1–2 cm, depending on Breslow depth. Narrow margins have not been shown to worsen survival in these trials. More recently, refinements in Mohs surgery have allowed for the highest rate of local control when immunohistochemistry is employed, particularly for head and neck melanomas, which have a poor rate of local control with WLE. Perioperative issues include appropriate examination and counseling, consideration of sentinel lymph node biopsy, and taking patient preference into account. Safety of the various surgical modalities is related to the size of the excision and the delay between excision and repair, with advantages noted for smaller excisions and same-day repair.

Keywords

Melanoma Excision Mohs Surgery Complication 

References

  1. 1.
    SEER Cancer Statistics Factsheets: Melanoma of the skin. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/statfacts/html/melan.html. Accessed 1 Nov 2016.
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefGoogle Scholar
  3. 3.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality – All COD, Aggregated With State, Total U.S. (1969–2013 <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Analyzed with: Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 8.3.2.
  4. 4.
    Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
  5. 5.
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013) <Katrina/Rita Population Adjustment> − Linked To County Attributes – Total U.S., 1969–2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission. Analyzed with: Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 8.3.2.
  6. 6.
    NAACCR Fast Stats: An interactive tool for quick access to key NAACCR cancer statistics. North American Association of Central Cancer Registries. http://www.naaccr.org/. Accessed on 28 Jan 2017.
  7. 7.
    Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer. 1989;63(2):386–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Evans RD, Kopf AW, Lew RA, et al. Risk factors for the development of malignant melanoma--I: Review of case-control studies. J Dermatol Surg Oncol. 1988;14(4):393–408.CrossRefPubMedGoogle Scholar
  9. 9.
    Williams ML, Sagebiel RW. Melanoma risk factors and atypical moles. West J Med. 1994;160(4):343–50.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. Int J Cancer. 1995;62:367–76.CrossRefPubMedGoogle Scholar
  11. 11.
    Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. J Am Acad Dermatol. 2016;74(3):411–20.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Parkin DM, Mesher D, Sasieni P. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer. 2011;105(Suppl 2):S66–9.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pfahlberg A, Kolmel K-F, Gefeller O. Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation-induced melanoma. Br J Dermatol. 2001;144(3):471–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Ghiasvand R, Rueegg CS, Weiderpass E, Green AC, Lund E, Veierød MB. Indoor tanning and melanoma risk: long-term evidence from a prospective population-based cohort study. Am J Epidemiol. 2017;185(3):147–56.PubMedGoogle Scholar
  15. 15.
    Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol. 2011;29(3):257–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Lens MB, Nathan P, Bataille V. Excision margins for primary cutaneous melanoma: updated pooled analysis of randomized controlled trials. Arch Surg. 2007;142(9):885–91.CrossRefPubMedGoogle Scholar
  18. 18.
    National Comprehensive Cancer Network. Melanoma (Version 1.2017). https://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf. Accessed 21 Mar 2017.
  19. 19.
    Abide JM, Nahai F, Bennett RG. The meaning of surgical margins. Plast Reconstr Surg. 1984;73(3):492–7.CrossRefPubMedGoogle Scholar
  20. 20.
  21. 21.
    Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(2 Pt 1):236–45.CrossRefPubMedGoogle Scholar
  22. 22.
    Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52(1):92–100.CrossRefPubMedGoogle Scholar
  23. 23.
    Temple CL, Arlette JP. Mohs micrographic surgery in the treatment of lentigo maligna and melanoma. J Surg Oncol. 2006;94(4):287–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Etzkorn JR, Sobanko JF, Elenitsas R, et al. Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. J Am Acad Dermatol. 2015;72(5):840–50.  https://doi.org/10.1016/j.jaad.2015.01.007.CrossRefPubMedGoogle Scholar
  25. 25.
    Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol Surg. 2004;30(3):403–8.PubMedGoogle Scholar
  26. 26.
    Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. 2004;140(5):552–8.  https://doi.org/10.1001/archderm.140.5.552.CrossRefPubMedGoogle Scholar
  27. 27.
    Mahoney MH, Joseph M, Temple CL. The perimeter technique for lentigo maligna: an alternative to Mohs micrographic surgery. J Surg Oncol. 2005;91(2):120–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the “square” procedure. J Am Acad Dermatol. 1997;37(5 Pt 1):758–64.CrossRefPubMedGoogle Scholar
  29. 29.
    Anderson KW, Baker SR, Lowe L, Su L, Johnson TM. Treatment of head and neck melanoma, lentigo maligna subtype: a practical surgical technique. Arch Facial Plast Surg. 2001;3(3):202–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Clayton BD, Leshin B, Hitchcock MG, Marks M, White WL. Utility of rush paraffin-embedded tangential sections in the management of cutaneous neoplasms. Dermatol Surg. 2000;26:671–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Hagerty RC, Worsham GF Jr, Rutland ED Jr, Hagerty RF. Peripheral in-continuity tissue examination. Plast Reconstr Surg. 1989;83(3):539–45.CrossRefPubMedGoogle Scholar
  32. 32.
    Schmid-Wendtner MH, Brunner B, Konz B, et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol. 2000;43:477–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol. 2002;146:1042–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna mela- noma. Int J Radiat Oncol Biol Phys. 1983;9:1019–21.CrossRefPubMedGoogle Scholar
  35. 35.
    Guadagnolo BA, Prieto V, Weber R, Ross MI, Zagars GK. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer. 2014;120:1361–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Dawber RP, Wilkinson JD. Melanotic freckle of Hutchinson: treatment of macular and nodular phases with cryotherapy. Br J Dermatol. 1979;101:47–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Ames FC, Balch CM, Reintgen D. Local recurrences and their management. In: Balch CM, Houghton Jr A, Milton GSA, Soong S, editors. Cutaneous melanoma. 2nd ed. Philadelphia: Lippincott; 1992. p. 287–94.Google Scholar
  38. 38.
    Balch CM, Soong S-J, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol. 2001;8:101–8.PubMedGoogle Scholar
  39. 39.
    DeBloom JR 2nd, Zitelli JA, Brodland DG. The invasive growth potential of residual melanoma and melanoma in situ. Dermatol Surg. 2010;36(8):1251–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet. 1907;169:996–1003.CrossRefGoogle Scholar
  41. 41.
    Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218:262–7.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol. 1996;3:446–52.CrossRefPubMedGoogle Scholar
  43. 43.
    Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol. 1998;14:272–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;26:438–41.CrossRefGoogle Scholar
  45. 45.
    Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primar y cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. [Erratum in: N Engl J Med 1991; 325: 292]. N Engl J Med. 1988;318(18):1159–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer. 2000;89:1495–501.CrossRefPubMedGoogle Scholar
  47. 47.
    Ringborg U, Andersson R, Eldh J, et al. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer. 1996;77:1809–14.CrossRefPubMedGoogle Scholar
  48. 48.
    Banzet P, Thomas A, Vuillemin E, et al. Wide versus narrow surgical excision in thin (<2mm) stage 1 primary cutaneous melanoma: long term results of a French multicentre prospective randomized trial on 319 patients. Proc Am Soc Clin Oncol. 1993;12:387.Google Scholar
  49. 49.
    Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97:1941–6.CrossRefPubMedGoogle Scholar
  50. 50.
    Thomas JM, Newton-Bishop J, A’Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757–66.CrossRefPubMedGoogle Scholar
  51. 51.
    Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. Lancet Oncol. 2016;17(2):184–92.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet. 2011;378(9803):1635–42.CrossRefPubMedGoogle Scholar
  53. 53.
    Balch CM. Surgical margins for melanoma: is 2 cm too much? ANZ J Surg. 2002;72(4):251–2.CrossRefPubMedGoogle Scholar
  54. 54.
    Hudson LE, Maithel SK, Carlson GW, et al. 1 or 2 cm margins of excision for T2 melanomas: do they impact recurrence or survival? Ann Surg Oncol. 2013;20(1):346–51.CrossRefPubMedGoogle Scholar
  55. 55.
    Moncrieff M, Henderson M. MelmarT melanoma margins trial investigating 1 cm vs 2 cm wide excision margins for primary cutaneous melanoma. Trial number: NCT02385214. Clinicaltrials.gov. 2015. Accessed 11 Sept 2016.
  56. 56.
    Wheatley K, Wilson JS, Gaunt P, Marsden JR. Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation. Cancer Treat Rev. 2016;42:73–81.CrossRefPubMedGoogle Scholar
  57. 57.
    Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(3 Pt 1):422–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Valentín-Nogueras SM, Brodland DG, Zitelli JA, González-Sepúlveda L, Nazario CM. Mohs micrographic surgery using MART-1 Immunostain in the treatment of invasive melanoma and melanoma in situ. Dermatol Surg. 2016;42(6):733–44.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Hunger RE, Seyed Jafari SM, Angermeier S, et al. Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome. Br J Dermatol. 2014;171:1391–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Lee KT, Kim EJ, Lee DY, Kim JH, Jang KT, Mun GH. Surgical excision margin for primary acral melanoma. J Surg Oncol. 2016;114(8):933–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Balch CM, Houghton AN, Milton GW, et al. Cutaneous melanoma. 2nd ed. Clinical management and treatment results worldwide. Philadelphia: JB Lippincott; 1992.Google Scholar
  62. 62.
    O’Brien CJ, Coates AS, Petersen-Shaefer K, Shannon K, Thompson JF, Milton GW, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991;162:310–4.CrossRefPubMedGoogle Scholar
  63. 63.
    Rawlani R, Rawlani V, Qureshi HA, Kim JY, Wayne JD. Reducing margins of wide local excision in head and neck melanoma for function and cosmesis: 5-year local recurrence-free survival. J Surg Oncol. 2015;111(7):795–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Mohs FE. Chemosurgical treatment of melanoma; a microscopically controlled method of excision. Arch Dermatol Syphilol. 1950;62(2):269–79.CrossRefGoogle Scholar
  65. 65.
    Chin-Lenn L, Murynka T, McKinnon JG, Arlette JP. Comparison of outcomes for malignant melanoma of the face treated using Mohs micrographic surgery and wide local excision. Dermatol Surg. 2013;39(11):1637–45.CrossRefPubMedGoogle Scholar
  66. 66.
    Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: university of Minnesota experience. Dermatol Surg. 2006;32(5):690–6.PubMedGoogle Scholar
  67. 67.
    Doss LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys. 1982;8(7):1131–4.CrossRefPubMedGoogle Scholar
  68. 68.
    Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. J Am Acad Dermatol. 2012;67(1):60–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Harwood AR. Conventional radiotherapy in the treatment of lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol. 1982;6(3):310–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U. The clinical behavior of desmoplastic melanoma. Am J Surg. 2001;182(6):590–5.CrossRefPubMedGoogle Scholar
  71. 71.
    Vongtama R, Safa A, Gallardo D, Calcaterra T, Juillard G. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck. 2003;25(6):423–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Chen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer. 2008;113(10):2770–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014;120(9):1369–78.CrossRefPubMedGoogle Scholar
  74. 74.
    Etzkorn JR, Sobanko JF, Shin TM, et al. Correlation between appropriate use criteria and the frequency of subclinical spread or reconstruction with a flap or graft for melanomas treated with Mohs surgery with melanoma antigen recognized by T cells 1 immunostaining. Dermatol Surg. 2016;42(4):471–6.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Lawrence CM, Rahim R, Charlton F, Husain A. Prospective study of formalin-fixed Mohs surgery and haematoxylin and eosin stains with control contralateral biopsies for lentigo maligna: 5-year follow-up results. Br J Dermatol. 2014;171(2):298–303.CrossRefPubMedGoogle Scholar
  76. 76.
    Bartlett EK, Gupta M, Datta J, et al. Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2014;21(3):1016–23.CrossRefPubMedGoogle Scholar
  77. 77.
    Kelly JW, Sagebiel RW, Calderon W, Murillo L, Dakin RL, Blois MS. Ann Surg. 1984;200(6):759–63.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Elder DE, Guerry D 4th, Heiberger RM, et al. Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg. 1983 Jan;71(1):66–72.CrossRefPubMedGoogle Scholar
  79. 79.
    Teng J, Halbert T, McMurry TL, Levine PA, Christophel JJ. Histopathologic margin distance in survival in resection of cutaneous melanoma of the head and neck. Laryngoscope. 2015 Aug;125(8):1856–60.CrossRefPubMedGoogle Scholar
  80. 80.
    Haydu LE, Stollman JT, Scolyer RA, et al. Minimum safe pathologic excision margins for primary cutaneous melanomas (1–2 mm in thickness): analysis of 2131 patients treated at a single center. Ann Surg Oncol. 2016;23(4):1071–81.CrossRefPubMedGoogle Scholar
  81. 81.
    Buck D II, Rawlani V, Wayne J, et al. Cosmetic outcomes following head and neck melanoma reconstruction: the patient’s perspective. Can J Plast Surg. 2012;20(1):e10–5.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Tseng JF, Tanabe KK, Gadd MA, et al. Surgical management of primary cutaneous melanomas of the hands and feet. Ann Surg. 1997;225(5):544–50.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Terushkin V, Brodland DG, Sharon DJ, Zitelli JA. Digit-sparing Mohs surgery for melanoma. Dermatol Surg. 2016;42(1):83–93.CrossRefPubMedGoogle Scholar
  84. 84.
    Stigall LE, Brodland DG, Zitelli JA. The use of Mohs micrographic surgery (MMS) for melanoma in situ (MIS) of the trunk and proximal extremities. J Am Acad Dermatol. 2016;75(5):1015–21.CrossRefPubMedGoogle Scholar
  85. 85.
    Mendese G, Maloney M, Bordeaux J. To scoop or not to scoop: the diagnostic and therapeutic utility of the scoop-shave biopsy for pigmented lesions. Dermatol Surg. 2014;40(10):1077–83.CrossRefPubMedGoogle Scholar
  86. 86.
    Stell VH, Norton HJ, Smith KS, Salo JC, White RL Jr. Method of biopsy and incidence of positive margins in primary melanoma. Ann Surg Oncol. 2007;14(2):893–8.CrossRefPubMedGoogle Scholar
  87. 87.
    Neila J, Soyer HP. Key points in dermoscopy for diagnosis of melanomas, including difficult to diagnose melanomas, on the trunk and extremities. J Dermatol. 2011;38(1):3–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21(1):175–83.CrossRefPubMedGoogle Scholar
  90. 90.
    Kyrgidis A, Tzellos T, Mocellin S, et al. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. Cochrane Database Syst Rev. 2015;5:CD010307.Google Scholar
  91. 91.
    Dixon A, Steinman H, Anderson S, Nirenberg A, Dixon J. Routine usage of sentinel node biopsy in melanoma management must cease. Br J Dermatol. 2016;175(6):1340–1.CrossRefPubMedGoogle Scholar
  92. 92.
    Patel SA, Liu JJ, Murakami CS, Berg D, Akkina SR, Bhrany AD. Complication rates in delayed reconstruction of the head and neck after Mohs micrographic surgery. JAMA Facial Plast Surg. 2016;18(5):340–6.CrossRefPubMedGoogle Scholar
  93. 93.
    Borah GL, Rankin MK. Appearance is a function of the face. Plast Reconstr Surg. 2010;125(3):873–8.CrossRefPubMedGoogle Scholar
  94. 94.
    Sniezek PJ, Brodland DG, Zitelli JA. A randomized controlled trial comparing acetaminophen, acetaminophen and ibuprofen, and acetaminophen and codeine for postoperative pain relief after Mohs surgery and cutaneous reconstruction. Dermatol Surg. 2011;37(7):1007–13.CrossRefPubMedGoogle Scholar
  95. 95.
    Read RL, Pasquali S, Haydu L, et al. Quality assurance in melanoma surgery: the evolving experience at a large tertiary referral centre. Eur J Surg Oncol. 2015;41(7):830–6.CrossRefPubMedGoogle Scholar
  96. 96.
    Reddy S, El-Haddawi F, Fancourt M, et al. The incidence and risk factors for lower limb skin graft failure. Dermatol Res Pract. 2014;2014:582080.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Merritt BG, Lee NY, Brodland DG, Zitelli JA, Cook J. The safety of Mohs surgery: a prospective multicenter cohort study. J Am Acad Dermatol. 2012;67(6):1302–9.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Hussain W, Affleck A, Al-Niaimi F, et al. Safety, complications and patients’ acceptance of Mohs micrographic surgery (MMS) under local anaesthesia – results from the UK MAPS (Mohs Acceptance and Patient Safety) collaboration group. Br J Dermatol. 2017;176(3):806–8.CrossRefPubMedGoogle Scholar
  99. 99.
    Jejurikar SS, Borschel GH, Johnson TM, Lowe L, Brown DL. Immediate, optimal reconstruction of facial lentigo maligna and melanoma following total peripheral margin control. Plast Reconstr Surg. 2007;120(5):1249–55.CrossRefPubMedGoogle Scholar
  100. 100.
    Trotter SC, Sroa N, Winkelmann RR, Olencki T, Bechtel M. A global review of melanoma follow-up guidelines. J Clin Aesth Dermatol. 2013;6(9):18–26.Google Scholar
  101. 101.
    Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann Surg Oncol. 2017;24(4):939–46.CrossRefPubMedGoogle Scholar
  102. 102.
    Jones MS, Torisu-Itakura H, Flaherty DC, et al. Second primary melanoma: risk factors, histopathologic features, survival, and implications for follow-up. Am Surg. 2016;82(10):1009–13.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129–42.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • David Panther
    • 1
  • David G. Brodland
    • 2
    • 3
  1. 1.Department of DermatologyWalla Walla ClinicWalla WallaUSA
  2. 2.Z & B Skin Cancer CenterPittsburghUSA
  3. 3.Departments of Dermatology, Otolaryngology & Plastic SurgeryUniversity of PittsburghPittsburghUSA

Personalised recommendations